Skip to main content

Table 1 Cohort characteristics

From: The therapeutic HIV Env C5/gp41 vaccine candidate Vacc-C5 induces specific T cell regulation in a phase I/II clinical study

 

All (n = 36)

Low dose (n = 12)

Medium dose (n = 12)

High dose (n = 12)

Age (years)

44.0 (38.5–49.7)a

45.2 (37.7–52.1)

46.3 (37.2–49.7)

42.7 (40.0–45.7)

Time since diagnosis (years)

5.2 (3.1–9.8)

4.9 (2.7–7.1)

5.0 (3.1–10.1)

8.7 (4.1–15.8)

Time on ART (years)

2.3 (1.4–3.9)

2.3 (1.6–2.7)

2.6 (1.7–4.1)

1.9 (1.3–6.6)

Nadir CD4 (cells/μl)

290 (234–360)

341 (265–396)

283 (234–343)

283 (227–358)

CD4 (cells/μl)

626 (529–758)

656 (572–756)

560 (526–679)

654 (557–831)

CD8 (cells/μl)

1051 (794–1250)

1109 (795–1223)

1032 (668–1282)

986 (805–1234)

HIV RNA (copies/ml)

0b(0 - <20)

0 (0 - <20)

0 (0 - <20)

0 (0 - <20)

  1. No differences between the groups
  2. aMedian (interquartile range)
  3. b0 implies undetectable PCR product